Figure 3. Role of Prednisone in Preventing Nevirapine-Associated Toxicities
Abbreviations: qd = once daily; bid = twice daily; d = day
In this randomized, double-blinded trial, patients starting on a nevirapine-based antiretroviral regimen also received a 14-day course of either prednisone (30 mg/d) or placebo. Patients received nevirapine at a dose of 200 mg qd x 14 days followed by 200 mg bid. A total of 75 patients in the study were evaluable (39 in the prednisone group and 36 in the control group). Follow-up occurred until week 24. This figure shows the percentage of patients who developed rash or hepatotoxicity in the prednisone and control groups. Data for this figure are taken from Knobel H, Miro JM, Domingo P, et al. Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial: the GESIDA 09/99 study. J Acquir Immune Defic Syndr. 2001;28:14-8.
From: HIV Web Study <www.hivwebstudy.org>